IL265121A - - Google Patents

Info

Publication number
IL265121A
IL265121A IL26512119A IL26512119A IL265121A IL 265121 A IL265121 A IL 265121A IL 26512119 A IL26512119 A IL 26512119A IL 26512119 A IL26512119 A IL 26512119A IL 265121 A IL265121 A IL 265121A
Authority
IL
Israel
Application number
IL26512119A
Other languages
English (en)
Other versions
IL265121B1 (en
IL265121B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL265121A publication Critical patent/IL265121A/en
Publication of IL265121B1 publication Critical patent/IL265121B1/en
Publication of IL265121B2 publication Critical patent/IL265121B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
IL265121A 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof IL265121B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Publications (3)

Publication Number Publication Date
IL265121A true IL265121A (cg-RX-API-DMAC7.html) 2019-04-30
IL265121B1 IL265121B1 (en) 2023-07-01
IL265121B2 IL265121B2 (en) 2023-11-01

Family

ID=59887401

Family Applications (3)

Application Number Title Priority Date Filing Date
IL303650A IL303650B2 (en) 2016-09-02 2017-09-01 Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
IL315821A IL315821A (en) 2016-09-02 2017-09-01 Group 2 stable trimers of the stem region of influenza hemagglutinin and their uses
IL265121A IL265121B2 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL303650A IL303650B2 (en) 2016-09-02 2017-09-01 Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
IL315821A IL315821A (en) 2016-09-02 2017-09-01 Group 2 stable trimers of the stem region of influenza hemagglutinin and their uses

Country Status (11)

Country Link
US (3) US11338033B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506938A1 (cg-RX-API-DMAC7.html)
JP (3) JP7183149B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240042570A (cg-RX-API-DMAC7.html)
CN (2) CN110167585B (cg-RX-API-DMAC7.html)
AU (2) AU2017321883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019004189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035443A1 (cg-RX-API-DMAC7.html)
IL (3) IL303650B2 (cg-RX-API-DMAC7.html)
SG (2) SG11201901790YA (cg-RX-API-DMAC7.html)
WO (1) WO2018045308A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CA3035443A1 (en) * 2016-09-02 2018-03-08 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
WO2020163719A2 (en) 2019-02-08 2020-08-13 The Usa, As Represented By The Secretary, Department Of Health And Human Services Nanoparticle-based influenza virus vaccines and uses thereof
WO2021174132A2 (en) * 2020-02-26 2021-09-02 The Wistar Institute Of Anatomy & Biology Compositions comprising self-assembling vaccines and methods of using the same
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022200582A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
JP2024528504A (ja) 2021-06-28 2024-07-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規インフルエンザ抗原
EP4401767A1 (en) 2021-09-16 2024-07-24 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
JP4873860B2 (ja) 2002-08-30 2012-02-08 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
WO2007032241A1 (ja) 2005-09-12 2007-03-22 Japan Science And Technology Agency 微粒子-タンパク質複合体およびその作製方法、半導体装置、蛍光標識方法
EP2476432B1 (en) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
CA2673994A1 (en) 2006-12-29 2008-07-24 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
EP3040082A1 (en) 2007-05-31 2016-07-06 Statens Serum Institut Influenza vaccines
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
JP6088123B2 (ja) 2008-02-01 2017-03-01 アルファ−オー・ペプチドズ・アーゲーAlpha−O Peptides Ag ワクチンとして有用な自己会合ペプチドナノ粒子
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
JP5551780B2 (ja) 2009-09-22 2014-07-16 メディカゴ インコーポレイテッド 植物由来のタンパク質を調製する方法
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
CN102858368B (zh) 2010-02-18 2017-04-12 泰科诺瓦有限公司 通用病毒样颗粒(vlp)流感疫苗
WO2012082634A1 (en) * 2010-12-13 2012-06-21 University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
CA2849822C (en) * 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
EP2785372B1 (en) * 2011-11-28 2019-06-19 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2013177444A2 (en) 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
CN108641002A (zh) * 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
BR112015029635B1 (pt) 2013-05-30 2023-05-02 Janssen Vaccines & Prevention B.V Polipeptídeo do domínio de haste da hemaglutinina da gripe e composição
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
US10125374B2 (en) * 2013-10-28 2018-11-13 Blue Sky Vaccines Gmbh Influenza virus vector for virotherapy
DK3148578T5 (da) * 2014-05-27 2024-10-14 Us Health Stabiliserede influenza-hæmagglutininstammeområdetrimerer og anvendelser deraf
JP7094103B2 (ja) * 2014-07-10 2022-07-01 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチンおよびその使用
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
CN107427571A (zh) 2014-12-31 2017-12-01 美利坚合众国,由健康及人类服务部部长代表 基于纳米颗粒的新型多价疫苗
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CA3035443A1 (en) * 2016-09-02 2018-03-08 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Also Published As

Publication number Publication date
IL315821A (en) 2024-11-01
IL303650B2 (en) 2025-02-01
IL265121B1 (en) 2023-07-01
AU2022246465B2 (en) 2024-05-30
BR112019004189A2 (pt) 2019-06-25
AU2017321883B2 (en) 2022-07-07
US20190192651A1 (en) 2019-06-27
SG11201901790YA (en) 2019-03-28
US20240050554A1 (en) 2024-02-15
JP2019537424A (ja) 2019-12-26
CN118146389A (zh) 2024-06-07
KR20240042570A (ko) 2024-04-02
CN110167585A (zh) 2019-08-23
EP3506938A1 (en) 2019-07-10
JP7500692B2 (ja) 2024-06-17
IL303650A (en) 2023-08-01
IL265121B2 (en) 2023-11-01
SG10201912944QA (en) 2020-02-27
KR20190056382A (ko) 2019-05-24
CN110167585B (zh) 2024-03-08
JP7183149B2 (ja) 2022-12-05
AU2022246465A1 (en) 2022-11-17
WO2018045308A1 (en) 2018-03-08
US20220339278A1 (en) 2022-10-27
AU2017321883A1 (en) 2019-04-18
JP2023018073A (ja) 2023-02-07
US11793871B2 (en) 2023-10-24
IL303650B1 (en) 2024-10-01
US11338033B2 (en) 2022-05-24
JP2024123036A (ja) 2024-09-10
CA3035443A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
IL265121A (cg-RX-API-DMAC7.html)
BR112018071172A2 (cg-RX-API-DMAC7.html)
BR102016015741A2 (cg-RX-API-DMAC7.html)
BE2016C036I2 (cg-RX-API-DMAC7.html)
CN303538864S (cg-RX-API-DMAC7.html)
CN303539241S (cg-RX-API-DMAC7.html)
CN303611063S (cg-RX-API-DMAC7.html)
CN303590673S (cg-RX-API-DMAC7.html)
CN303586233S (cg-RX-API-DMAC7.html)
CN303565077S (cg-RX-API-DMAC7.html)
CN303551287S (cg-RX-API-DMAC7.html)
CN303547670S (cg-RX-API-DMAC7.html)
CN303539752S (cg-RX-API-DMAC7.html)
CN303539449S (cg-RX-API-DMAC7.html)
CN303539407S (cg-RX-API-DMAC7.html)
CN303539371S (cg-RX-API-DMAC7.html)
CN303647322S (cg-RX-API-DMAC7.html)
CN303539296S (cg-RX-API-DMAC7.html)
CN303539290S (cg-RX-API-DMAC7.html)
CN303537910S (cg-RX-API-DMAC7.html)
CN303539118S (cg-RX-API-DMAC7.html)
CN303539063S (cg-RX-API-DMAC7.html)
CN303538945S (cg-RX-API-DMAC7.html)
CN303538883S (cg-RX-API-DMAC7.html)
CN303537993S (cg-RX-API-DMAC7.html)